IBS, Fully Understood: Beyond Reassurance Medicine — A Modern Guide to Mechanism, Testing, and the Cellular Frontier

Irritable bowel syndrome is the most common condition I see in my clinic, and it is also the most frequently mishandled. Patients arrive having been told, often kindly and often repeatedly, that their tests are normal, that they should try a low-FODMAP diet, and that an antispasmodic such as Colofac should help. They leave feeling reassured but not better, and within months they are back — or worse, they stop coming, and quietly accept a diminished quality of life. This is not medicine's finest chapter. IBS is a real biological condition, not a diagnosis of exclusion, not a psychological label, and not a dumping ground for unexplained symptoms. It has identifiable mechanisms, testable abnormalities, and a genuine therapeutic ladder that extends far beyond reassurance and mebeverine. This article is the map I wish every patient with IBS had been given on the day they were first told the diagnosis.

The Five Interwoven Mechanisms of IBS

Modern IBS is best understood not as a single disease but as a final common pathway. Five mechanisms converge to produce the symptoms — abdominal pain, bloating, urgency, and altered bowel habit — and in any given patient, one or two of them tend to dominate. The first is the microbiome: most patients with IBS show measurable alterations in gut bacterial composition and diversity, and some show frank overgrowth of the small bowel. The second is diet, or more precisely the interaction between specific foods and an already-sensitised gut, where fermentable carbohydrates, gluten-containing grains, and individual triggers generate disproportionate symptoms. The third is the gut-brain axis, the bidirectional superhighway along which signals of stress, emotion, and cognitive state reshape gut motility and sensation in real time; we explore that network in detail in our companion piece, The Gut-Brain Axis Explained. The fourth is visceral hypersensitivity, in which the sensory nerves of the gut fire at lower thresholds, so that a normal volume of gas or a normal contraction is experienced as painful. The fifth is psychology — not as a cause to be dismissed, but as a genuine modulator, with stress, anxiety, depression, early-life adversity, and trauma each shifting the gut's sensitivity and responsiveness. These mechanisms do not sit in separate compartments; they loop back on one another. An altered microbiome produces metabolites that sensitise nerves; sensitised nerves amplify the brain's stress response; the stress response alters motility; altered motility changes the microbiome. Treating IBS means recognising which loops are active in this patient, and interrupting them at the right points.

The five interwoven mechanisms of IBS: each connects to the others in bidirectional loops, and any one of them can be the dominant driver in a given patient.

Step One: Exclude the Serious Disease

Before any of the therapeutic ladder is deployed, the first task is to make sure the symptoms are actually IBS and not something that looks like it. Alarm features — unintentional weight loss, rectal bleeding, iron deficiency anaemia, a family history of bowel cancer or inflammatory bowel disease, symptom onset after the age of 50, persistent nocturnal diarrhoea, or a recent change in a previously stable bowel habit — all demand structural investigation before IBS is even considered. Baseline blood tests, faecal calprotectin to screen for inflammation, coeliac serology, and a thyroid panel are routine. Colonoscopy is indicated for any alarm feature, and for most patients over 45 it will have been done anyway as part of bowel cancer screening. Gastroscopy is added if there is upper GI overlap or if microscopic causes of diarrhoea are suspected. A diagnosis of IBS made without excluding these conditions is not a diagnosis at all; it is a guess. The Rome IV criteria formalise the symptom pattern required for the diagnosis, but they assume the serious disease has been ruled out first.

Step Two: Symptom Relief While the Picture Clarifies

While investigation is underway, and for patients whose symptoms are mild or intermittent, targeted symptom relievers are a reasonable first line. Antispasmodics such as mebeverine (Colofac), peppermint oil capsules, and hyoscine reduce smooth muscle spasm and help with crampy pain and bloating. For diarrhoea-predominant IBS, loperamide is effective and underused. For constipation-predominant IBS, osmotic laxatives like macrogol, and in selected cases prucalopride or linaclotide, restore transit without the harshness of stimulant laxatives. For bloating, simethicone, dietary review, and in some cases rifaximin have a role. These agents are genuinely helpful in the right patient — but they are first-aid, not a strategy. If a patient is still taking Colofac three times a day six months into treatment and has not moved beyond it, the care plan has stalled.

Step Three: Dietary Modification — FODMAP Done Properly, Gluten, and Elimination

Diet is the single most powerful lever in IBS care, and it is also the most commonly misused. The low-FODMAP diet — reducing fermentable oligosaccharides, disaccharides, monosaccharides, and polyols — is evidence-based and effective in 60 to 75 per cent of patients, but it was never designed to be a lifelong way of eating. The correct protocol is a strict 2 to 6 week restriction phase, followed by a structured reintroduction phase in which each FODMAP group is tested individually, and a personalisation phase in which only the genuinely problematic foods are avoided. Done this way, low-FODMAP identifies the triggers and restores dietary variety; done the common way, as an indefinite restriction, it impoverishes the microbiome and worsens the underlying problem. A registered dietitian familiar with FODMAPs is worth their weight in gold. Beyond FODMAPs, gluten restriction has a subset of responders — non-coeliac gluten sensitivity is a real entity, distinct from coeliac disease, and a trial of strict gluten avoidance for 4 to 6 weeks is reasonable when symptoms suggest it. Structured elimination diets, supervised food-symptom diaries, and in some cases histamine-directed dietary strategies complete the dietary toolkit. Diet is not a monolith, and the question is never "should this patient go gluten-free?" but "which dietary strategy, done for how long, will most efficiently identify this patient's personal triggers?"

Step Four: The Microbiome Investigation — SIBO, IMO, and Fungal Overgrowth

Patients who remain symptomatic despite optimised diet and who have prominent bloating, distension, or early postprandial discomfort deserve a focused look at the small bowel microbiome. Small intestinal bacterial overgrowth (SIBO) occurs when colonic-type bacteria colonise the normally sparsely populated small bowel and ferment carbohydrates within minutes of eating; it is diagnosed with a lactulose or glucose breath test measuring hydrogen production. Intestinal methanogen overgrowth (IMO, previously called methane-predominant SIBO) is driven by archaea rather than bacteria, produces methane on breath testing, and is more strongly associated with constipation and severe bloating. Small intestinal fungal overgrowth (SIFO) is increasingly recognised, particularly in patients with repeated antibiotic courses, immunosuppression, or refractory symptoms despite negative bacterial testing. Treatment is targeted to the organism identified: rifaximin for hydrogen-dominant SIBO, rifaximin combined with neomycin or metronidazole for methane-dominant IMO, and antifungal agents such as fluconazole or nystatin for SIFO. Each of these conditions has a real recurrence rate and benefits from a post-treatment strategy that includes prokinetics, dietary scaffolding, and attention to underlying motility. A patient whose IBS suddenly responds to a two-week course of rifaximin has not had their IBS cured by magic; they have had an unrecognised SIBO treated.

Step Five: Microbiome Restoration and Faecal Microbiota Transplant

For selected patients with well-characterised dysbiosis who have not responded to dietary and antimicrobial strategies, microbiome-directed therapies move into view. Strain-specific probiotics — not supermarket multi-strains, but targeted agents with evidence in IBS, such as Bifidobacterium infantis 35624 or certain Lactobacillus plantarum preparations — can meaningfully reduce symptoms in a subset. Prebiotic fibres are introduced gradually and cautiously, because what nourishes a healthy microbiome can inflame a dysbiotic one. Faecal microbiota transplant (FMT), the transfer of a screened donor microbiome to the recipient's gut, has moved beyond Clostridioides difficile into active investigation in IBS, with modest but real symptom improvement in refractory cases, particularly diarrhoea-predominant IBS. FMT in IBS is not yet first-line, and not every patient is a candidate, but it is no longer experimental; it is a considered option for the right person. The other emerging strategy in this space is personalised dietary rebuilding — using sequencing of the patient's stool microbiome to guide which fibres, fermented foods, and targeted prebiotics to introduce in what order. It is one of the most active research areas in gastroenterology, and it is no longer the preserve of research protocols alone.

A patient who has tried one diet, one medication, and one round of reassurance has not exhausted the treatment of IBS. They have begun it.

Step Six: The Cellular Frontier — Confocal Laser Endomicroscopy

The most exciting development in IBS care in a decade is not a new drug or a new diet. It is the ability to see the gut at cellular resolution, in real time, during endoscopy. Confocal laser endomicroscopy (CLE) is a technique in which a miniature laser microscope at the tip of the endoscope generates thousand-times-magnified images of the intestinal lining, visualising individual epithelial cells, capillary loops, and the junctions between cells that form the gut barrier. When a suspected trigger food is applied topically to the duodenal mucosa during the procedure, a minority of IBS patients show, within minutes, a dramatic and reproducible cellular response: widening of the epithelial intercellular spaces, increased intraepithelial lymphocytes, and leakage of fluorescein into the lumen — the cellular footprint of what patients and clinicians have long called "leaky gut" and of food-specific mucosal hypersensitivity. International studies have shown that this response predicts symptom improvement when the identified food is excluded, at a rate far higher than conventional allergy testing or symptom-based elimination. These findings are not detectable on any other test — not on blood work, not on colonoscopy, not on standard biopsy, and not on breath testing. Shore Gastroenterology will be offering confocal laser endomicroscopy with food-trigger testing from late 2026, as the first service of its kind in Australia, for patients with refractory IBS and suspected food-driven mucosal hypersensitivity. This is precisely the kind of precision medicine that IBS care has been waiting for.

The six-step IBS management ladder: a modern patient has access to every rung, not just the first two.

The Gut-Brain and Psychological Layer — Always Parallel, Never Optional

Every step of the ladder above works better when the gut-brain axis is addressed in parallel, not afterwards. This does not mean that IBS is a psychological condition or that patients are imagining their symptoms. It means that the brain is a powerful modulator of gut sensation and motility, and ignoring it makes the rest of the work harder. Gut-directed hypnotherapy has some of the best evidence in all of IBS, with response rates approaching 70 per cent in well-run programs and durable effects beyond a year. Cognitive behavioural therapy tailored for IBS, delivered in-person or through validated app-based programs, has comparable efficacy and is widely accessible. Low-dose tricyclic antidepressants, such as amitriptyline 10 to 25 mg at night, work not as antidepressants but as neuromodulators that reduce visceral hypersensitivity, and they are one of the most underused tools in IBS care. SSRIs and SNRIs have a role in patients with significant comorbid anxiety or depression. Addressing sleep, stress, and where relevant, trauma, is not an add-on to IBS treatment; it is part of the treatment.

What Shore Gastroenterology Is About

IBS is the condition that defines what kind of gastroenterology service you are practising. It is easy to do it badly: a standard consultation, a pamphlet, a script for mebeverine, and a referral to the internet for a FODMAP list. It is harder — and more worthwhile — to take the time to map the dominant mechanisms in the individual patient, exclude the serious disease properly, deploy the right dietary strategy with the right supervision, investigate the microbiome in the patients who need it, and, when the standard ladder has been exhausted, offer the cellular-level tools that are finally becoming available. That is the model of care Shore Gastroenterology is built around. We take IBS seriously because our patients take their symptoms seriously. We use the full diagnostic toolkit, not a narrow one. We collaborate with dietitians, psychologists, and gut-directed hypnotherapists rather than working in isolation. And from late 2026 we will be the first Australian service to offer confocal laser endomicroscopy with food-trigger testing, bringing cellular-resolution diagnosis to patients whose IBS has never been properly characterised. This is gastroenterology as it should be: precise, personal, and persistent.

When to See a Specialist

If your IBS has not been properly characterised — if no-one has ever asked you whether your dominant problem is pain, bloating, constipation, diarrhoea, or urgency; if you have never had a structured low-FODMAP trial with a reintroduction phase; if breath testing for SIBO and IMO has never been offered despite prominent bloating; if your gut-brain axis has been dismissed rather than addressed; or if you have been taking Colofac for more than a year without real improvement — a specialist review is warranted. If you have already done the basics and remain symptomatic, and if you suspect specific foods are triggering disproportionate reactions that nothing has been able to identify, the confocal laser endomicroscopy service we will be launching in late 2026 may be exactly the tool your case has been missing. Reach out through the Shore Gastroenterology clinic. IBS is one of the most treatable common conditions in gastroenterology when it is approached in full, and one of the most frustrating when it is not. The difference between those two experiences is almost always the depth of the assessment. We are here to offer the depth.